NCT03099031View on ClinicalTrials.gov

Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)

CompletedOBSERVATIONAL
Enrollment

420

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

May 15, 2017

Study Completion Date

May 15, 2017

Conditions
Venous Thromboembolism
Interventions
DRUG

Tinzaparin

Subcutaneous injection of 175 IU/kg once daily for 6 months

Trial Locations (1)

Unknown

George Pompidou European Hospital, Paris

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY

NCT03099031 - Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE) | Biotech Hunter | Biotech Hunter